AlzeCure Receives Additional Subscription Commitments of Approximately SEK 7 million in the Ongoing Rights Issue

Yahoo

7 days ago

NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, WITHIN OR INTO THE AUSTRALIA, HONGKONG, JAPAN, CANADA, NEW ZEALAND, SINGAPORE, SOUTH AFRICA, THE UNITED STATES, RUSSIAN FEDERATION, BELARUS, SOUTH KOREA, SWITZERLAND OR ANY OTHER JURISDICTION IN WHICH SUCH PUBLICATION, DISTRIBUTION OR RELEASE WOULD BE CONTRAVENING TO ANY APPLICABLE RULES. ADDITIONAL RESTRICTIONS ARE APPLICABLE, PLEASE SEE "IMPORTANT INFORMATION" IN THE END OF THIS PRESS RELEASE.
STOCKHOLM, SE / / July 16, 2025 / AlzeCure Pharma (STO:ALZCUR)(FRA:AC6) - AlzeCure Pharma AB ("AlzeCure" or the "Company") has received additional subscription commitments of SEK 7 million from a group of qualified investors in the Company's ongoing rights issue announced on June 16, 2025 (the "Rights Issue"). Should the issue be oversubscribed, the Company intends to utilize the remaining portion of the Over-Allotment Option, following the previously announced additional subscription commitment, to accommodate these subscriptions to the greatest extent possible.
In addition to previously entered subscription commitments, a group of qualified investors have committed to subscribe for shares amounting to approximately SEK 7 million, corresponding to about 14 percent of the Rights Issue. The subscription commitments are based on the same terms as for other investors, i.e. no remuneration. In the event the issue is oversubscribed and the allocation under these additional subscription commitments cannot be fully allocated, the Company intends to utilize the remaining portion of the Over-Allotment Option of around SEK 5 million to accommodate theses subscription to the greatest extent possible in accordance with the principle that allocation under the overallotment option shall primarily be made to strategic and/or qualified investors.
Following these additional subscription commitments, the total amount of subscription commitments entered into amounts to approximately SEK 32 million, corresponding to around 66 percent of the total amount of the Rights Issue of approximately SEK 48.5 million, with an over-allotment option of SEK 10 million.
"At AlzeCure Pharma, we are very pleased with the interest and support we are seeing for the share issue, both from existing major shareholders and new investors. This demonstrates confidence in the share issue and the plans it is intended to finance, which primarily include preparations for the upcoming Phase 2 study in Alzheimer's patients with NeuroRestore ACD856 - a project for which we have secured funding from the European Innovation Council. We are very proud of this support, which can also be seen as a validation of the project," says Martin Jönsson, CEO of AlzeCure.
Additional subscription commitments:
Investor
Subscription commitment, SEK
Jan Poulsen
2,000,000
Niklas Estensson
1,000,000
Christian Månsson
1,000,000
Rose-Marie Karlsson
1,000,000
Alexander Schoeneck
1,000,000
AV Linbo Invest AB
660,000
Johan Wiklund
308,000
TOTAL
6,968,000
The subscription period for the share issue runs through July 22. More information is available at: www.alzecurepharma.com
Advisors
AlzeCure has engaged Zonda Partners AB and Synch Advokat AB as financial and legal advisors, respectively, in connection with the Rights Issue. In connection with the additional subscription commitment addressed in this press release, Corpura Fondkommission AB has also acted as joint bookrunner.
Important information
The information in this press release does not contain or constitute an offer to acquire, subscribe for, or otherwise trade in shares, subscription warrants, or other securities in AlzeCure. No action has been taken, and no actions will be taken, to permit a public offering in any jurisdiction other than Sweden. Any invitation to eligible persons to subscribe for shares in AlzeCure will only be made through the supplementary Information Document published by AlzeCure on 7 July 2025.
The information in this press release may not be announced, published, or distributed, directly or indirectly, in or into Australia, Hong Kong, Japan, Canada, New Zealand, Singapore, South Africa, the United States, Belarus, Russia, South Korea, Switzerland, or any other jurisdiction where such action would be unlawful, subject to legal restrictions, or would require actions other than those required under Swedish law. Any failure to comply with these restrictions may constitute a violation of applicable securities laws.
For more information, please contact
Martin Jönsson, CEOTel: [phone] [e-mail]
About AlzeCure Pharma AB (publ)
AlzeCure® is a Swedish pharmaceutical company that develops new innovative drug therapies for the treatment of severe diseases and conditions that affect the central nervous system, such as Alzheimer's disease and pain - indications for which currently available treatment is very limited. The company is listed on Nasdaq First North Premier Growth Market and is developing several parallel drug candidates based on three research platforms: NeuroRestore®, Alzstatin® and Painless.
NeuroRestore consists of two symptomatic drug candidates where the unique mechanism of action allows for multiple indications, including Alzheimer's disease, as well as cognitive disorders associated with traumatic brain injury, sleep apnea and Parkinson's disease. The Alzstatin platform focuses on developing disease-modifying and preventive drug candidates for early treatment of Alzheimer's disease and comprises two drug candidates. Painless is the company's research platform in the field of pain and contains two projects: ACD440, which is a drug candidate in the clinical development phase for the treatment of neuropathic pain, and TrkA-NAM, which targets severe pain in conditions such as osteoarthritis. AlzeCure aims to pursue its own projects through preclinical research and development through an early clinical phase, and is continually working on business development to find suitable outlicensing solutions with other pharmaceutical companies.
FNCA Sweden AB is the company's Certified Adviser. For more information, please visit www.alzecurepharma.se.
Attachments
AlzeCure Receives Additional Subscription Commitments of Approximately SEK 7 million in the ongoing Rights Issue
SOURCE: AlzeCure Pharma
View the original press release on ACCESS Newswire